Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies

BACKGROUND: Recently, brentuximab vedotin has become a promising therapeutic approach for CD30-positive hematological malignancies, but its role in other relapsed or refractory malignant lymphoma needs to be proven. Brentuximab vedotin was demonstrated effective, but no study has summarized the conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhe, Wang, Fei, Zhang, Hongming, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408955/
https://www.ncbi.nlm.nih.gov/pubmed/25945039
http://dx.doi.org/10.2147/DDDT.S83592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408955/
https://www.ncbi.nlm.nih.gov/pubmed/25945039
http://dx.doi.org/10.2147/DDDT.S83592

Ejemplares similares